National Institutes of Health · USA

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical…

Full title in the source: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

Offen

Die Einreichungsfrist endet am 3. Februar 2027. Antragsberechtigte Gruppen laut Quelle: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Small businesses und 12 weitere.

Frist: 3. Februar 2027 (in 80 Tagen)
Fördersumme: Nicht angegeben — siehe offizielle Ausschreibung
Förderquote: Kein Pflicht-Eigenanteil angegeben; Förderquote nicht angegeben
Eigenanteil: Nicht erforderlich
Wahrscheinliche Antragstellende: Gemeinnützige, Hochschulen & Forschung, KMU / Start-ups, Unternehmen, Öffentliche Stellen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber: National Institutes of Health
Referenz: PAR-25-026
Assistance Listing (USA): 93.233 National Center on Sleep Disorders Research; 93.837 Cardiovascular Diseases Research; 93.838 Lung Diseases Research; 93.839 Blood Diseases and Resources Research; 93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Zuletzt geprüft: 13. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Über diese Ausschreibung

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Wer kann sich bewerben?

Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Small businesses
City or township governments
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
For profit organizations other than small businesses
Private institutions of higher education
Independent school districts
Public housing authorities/Indian housing authorities
Special district governments
Native American tribal governments (Federally recognized)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Health

So bewerben Sie sich

Read the full notice of funding opportunity (NOFO) linked from the official page: eligibility, cost sharing and evaluation criteria.
Make sure your organisation has an active SAM.gov registration and Unique Entity ID (UEI); registration can take several weeks.
For NIH: the organisation and the principal investigator also need eRA Commons accounts; applications are usually submitted through Grants.gov (for example with ASSIST).
Prepare the required forms, narrative, budget and attachments exactly as the NOFO specifies.
Submit before the deadline and keep the tracking number. Check for amendments before you submit.

From the call text

Who can apply: Not stated in the call text we hold — check the official page
Company stage: Not stated in the call text we hold — check the official page
Single applicant or consortium: Not stated in the call text we hold — check the official page
Where applicants must be based: Not stated in the call text we hold — check the official page
Where to apply: Not stated in the call text we hold — check the official page

Kontakt

National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Offizielle Quellen

Offizielle Ausschreibungsseite · Programmseite des Fördergebers

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 13. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.